Peritoneal metastases are associated with reduced overall survival, as well as with significantly worse prognosis compared with non-peritoneal metastases. Systemic chemotherapeutic regimens have not achieved major benefits in OS. In patients with potentially resectable disease, surgical management of peritoneal metastases of colorectal origin has evolved profoundly in the past 15 years. HIPEC has sound theoretical benefits and its usefulness has been proven by retrospective trials and in comparison with systemic chemotherapy. The main goal of the trial was to assess the specific benefit of adding HIPEC to cytoreductive surgery in patients with colorectal peritoneal metastasis. We aim to review and discuss the results and implications of the trial in clinical practice.
Share it with your network and help spread clinical knowledge.
